Identification of interleukin-1-beta inhibitors in gouty arthritis using an integrated approach based on network pharmacology, molecular docking, and cell experiments

HIGHLIGHTS

SUMMARY

Interleukin-1 (IL-1) inhibitors are second-line drugs for GA, including direct inhibitors of interleukin-1 beta (IL-1β) (canakinumab and gevokizumab), selective inhibitors of IL-1 receptors (anakinra), and IL-1β receptor antagonist (rilonacept), but treatment-induced adverse reactions, especially those related to upper respiratory tract infections, abscesses, and gastrointestinal diseases, are still unavoidable. GA TCMSP OB ≥ 30% DL ≥ 0.18 OMIM database GeneCards database 133 eligible active compounds TFDC 242 Protein-Protein Interaction Intersection targets 25 TFDC-ActiveCompoundPotential Target-GA Network GA 191 GO and KEGG pathway enrichment analysis qPCR TFDC . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.